Abstract 191P
Background
Carcinotech's 3D bioprinted tumour models offer a transformative platform for advancing cancer drug screening and therapeutic testing by accurately replicating the complexity of the tumour microenvironment (TME). Unlike traditional 2D cultures, organoids, or animal models, these bioprints incorporate multiple cell types from patient-derived cancer tissues in a robust tissue matrix, providing a more biologically relevant model for preclinical studies, particularly in immuno-oncology and personalised medicine. Our recent research shows that these models effectively represent the presence of tumor-infiltrating lymphocytes (TILs), a crucial immune cell group targeted by advanced immunotherapies.
Methods
Patient ovarian tumour biopsies were sectioned, processed into FFPE blocks and TME characterised using immunofluorescence (IF) technique. Patient-derived cells were cultured as a heterogeneous population and 3D-bioprinted with custom bioink onto 96-well plate format. After 14 days in culture, characterisation of 3D-model TME composition was performed to compare it to the original tumour to assure high TME representation. Additionally, Carcino3D ovarian cancer models were treated with well-established immunotherapeutics Pembrolizumab and Rituximab, and activation of immune markers using IF as well as pro-inflammatory release of Granzyme B post-treatment tested.
Results
While the viability of the Carcino3D tumour model slightly declined after treatment, we observed stronger immune responses, including cytokine release, when treated with Pembrolizumab or Rituximab. Through advanced 3D imaging and AI-based analysis, we identified an increase in T-cell numbers post-treatment. Interestingly, early-stage T-cell activation decreased, while late-stage activation markers increased, confirming the models' accuracy in predicting therapeutic outcomes.
Conclusions
These findings highlight the potential of Carcinotech's 3D bioprinted models to significantly accelerate immunotherapy research and improve drug development pipelines. By offering a more dynamic and representative testing platform, these models promise to reshape the future of cancer drug discovery and personalised treatment approaches.
Legal entity responsible for the study
Carcinotech Ltd.
Funding
Carcinotech.
Disclosure
K. Pawlicka, M. McDonald, B. Kennedy, V. Metodieva, J. Adams: Financial Interests, Institutional, Full or part-time Employment: Carcinotech.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract